Small Lymphocytic Lymphoma — Trials

Small Lymphocytic Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

479 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 129
Recruiting: 67
Ph III recruiting: 9
Growth YoY: −23.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (108)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03801525	Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)(ULTRA-V)	terminated	Phase 2 / Phase 3	277	TG Therapeutics, Inc.INDUSTRY	1	Apr 19, 2024	clinicaltrials
NCT02793583	Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL)	terminated	Phase 2 / Phase 3	710	TG Therapeutics, Inc.